Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. Nieuws
  7. Andere talen
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Rapport
Real Time Euronext Bruxelles  -  17:35:16 31-01-2023
1.370 EUR   -0.72%
17/01Top Premarket stijgers
MT
2022Sectorupdate: Gezondheidszorgaandelen gaan woensdagmiddag vooruit
MT
2022Positieve winsten van Nike stuwen Amerikaanse aandelenfutures naar groen in aanloop naar gegevens over consumentenvertrouwen en huizenverkoop
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Nieuws in andere talen op CELYAD ONCOLOGY SA
17/01Top Premarket Gainers
2022Sector Update: Health Care Stocks Post Moderate Gains Amid Broader Market ..
2022Sector Update: Health Care Stocks Advancing Wednesday Afternoon
2022Upbeat Nike Earnings Drive US Equity Futures Into Green Ahead of Consumer Confidence, H..
2022Top Premarket Decliners
2022Celyad : arrêt du dernier programme clinique, le titre chute
2022Celyad Oncology Tanks 48% on Decision to Stop Developing Blood Cancer Drug CYAD-211
2022Celyad Oncology provides an update on its strategic business model, continuing to focus..
2022Celyad Oncology : Request for proposal of external statutory Auditor mandate
2022Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business High..
2022Celyad Oncology Provides Strategic Update
2022Celyad : met à jour sa stratégie d'entreprise
2022Celyad Oncology Provides Update on Clinical Trial Programs
2022Celyad Oncology to Divest Cell Therapy Facility in Belgium for $6 Million
2022Celyad Oncology : vend son usine belge à Cellistic
2022Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transa..
2022Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transa..
2022Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit ..
2022Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlight..
2022Celyad : 14,4 millions d'euros de trésorerie à la fin juin
2022Celyad Oncology : Reports First Half 2022 Financial Results and Recent Business Highlights..
2022Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2022
2022Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlight..
2022Celyad Oncology présente ses Résultats Financiers pour le premier semestre de l'année 2..
2022Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlight..
2022Les valeurs à suivre demain à la Bourse de Paris Vendredi 5 août 2022
2022Celyad Oncology : Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial - Form ..
2022Wall Street Futures Consolidate After Strong End to July
2022Top Premarket Gainers
2022Celyad Oncology Shares Rally After FDA Lifts Study Hold
2022Celyad : les essais de phase 1b vont reprendre
2022Celyad Oncology Says FDA Lifts Clinical Hold on Phase 1b Trial of Colorectal Cancer Com..
2022US FDA Lifts Clinical Hold on Celyad Oncology's Trial For CYAD-101
2022Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
2022Celyad Oncology Sa Announces Fda Lifts Clinical Hold of Cyad-101-002 Phase 1B Trial
2022Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call
2022Celyad : Filippo Petti démissionne du poste de CEO
2022Celyad Oncology : Announces Leadership Updates - Form 6-K
2022Celyad Oncology SA Announces Chief Financial Officer Changes
2022Celyad Oncology SA Announces Chief Executive Officer Changes
2022Celyad Oncology Names Michel Lussier Interim Chief Executive, Hilde Windels Chairwoman
2022Celyad Oncology Names New Chair, Interim CEO
2022Celyad Oncology Announces Leadership Updates
2022Celyad Oncology SA Announces Board Changes
2022Celyad Oncology : Summary Note – Listing Prospectus
2022Celyad Oncology : Security Note
2022Celyad Oncology : Registration Document
2022Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
2022Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Celyad Oncology : Ago - pv - fr
2022Celyad Oncology : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
2022Celyad Oncology : Letter to Shareholders – March 2022
2022Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021
2022Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
2022Celyad Oncology : to Announce Full Year 2021 Financial Results and Host Conference Call
2022Celyad : la suspension de l'essai de phase 1b confirmée
2022Celyad Says FDA Places Early-Stage Colorectal Cancer Trial on Clinical Hold
2022Celyad Oncology Slips 6% on US FDA's Clinical Hold on Colorectal Cancer Treatment Trial..
2022Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
2022Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
2022Global markets live: Bayer, HP, Shell, Toshiba, Citigroup...
2022Bolsa de Madrid: Indagación sobre Rusia
2022Haro sur la Russie
2022EN DIRECT DES MARCHES : Stellantis, Atos, TotalEnergies, EssilorLu..
2022Celyad Oncology : Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial - Form 6-K
2022Celyad : le titre chute après l'arrêt d'un essai de phase 1b
2022Celyad Pauses Early-Stage Colorectal Cancer Trial Amid Safety Issues
2022Celyad Oncology SA Announces Voluntary Pause of CYAD-101-002 Phase 1B Trial
2022Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
2022Celyad Oncology : Securities Note
2022Celyad Oncology : Summary Note – Listing Prospectus
2022Celyad Oncology Announces February 2022 Conference Schedule
2022Celyad Oncology : Provides Outlook for 2022 - Form 6-K
2022Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022
2021Avis d'analystes du jour : Zur Rose, McPhy, Aker BP, Brenntag, ..
2021Celyad Oncology Announces January 2022 Conference Schedule
2021Transparency notification received from Tolefi SA and related persons (Article 14 ß1 of..
2021Celyad Oncology Sa : Notification de Transparence de Tolefi SA (Article 14ß1 de la loi du ..
2021Celyad Oncology - Transparency notification received from Fortress Investment Group LLC
2021Celyad Oncology Doses First Patient in Trial of Colorectal Cancer Treatment
2021Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
2021Celyad Oncology SA Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial
2021Celyad Oncology : Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Me..
2021Celyad Oncology : Transparency Notification Fortress Investment Group LLC
2021Celyad : mises à jour sur deux programmes cliniques
2021Celyad Oncology SA Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annua..
2021Global markets live: Apple, Volkswagen, Uber, Rolls-Royce, Gamestop...
2021EN DIRECTO DESDE LOS MERCADOS: GameStop, Adobe, Ercros, Ib..
2021Gran incertidumbre sobre las previsiones para 2022
2021EN DIRECT DES MARCHES : Vivendi, Lagardère, TotaEnergies, Veolia, ..
2021Grand flou sur les prévisions 2022
2021Celyad Oncology Concludes $33 Million Private Placement
2021Celyad Oncology Closes $32.5 Million Share Sale to Fortress Investment Affiliate
2021Celyad Oncology : Announces Closing of $32.5 Million Private Placement with Fortress Inves..
2021Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Inve..
2021Celyad Oncology SA announced that it has received €28.73 million in funding from F..
2021Celyad Oncology : Report Accounting and financial info
2021Celyad Oncology Announces $32.5 Million Private Placement with Fortress
2021Health Care Stocks Drifting Lower Ahead of Weekend
2021Health Care Stocks Inching Lower But Outperform Most Industry Sectors
Volgende evenement op CELYAD ONCOLOGY SA